Unicycive Price To Sales Ratio vs Payables Turnover Analysis

UNCY Stock

USD 0.55 0.01 1.79%

Unicycive Therapeutics financial indicator trend analysis is much more than just breaking down Unicycive Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Unicycive Therapeutics is a good investment. Please check the relationship between Unicycive Therapeutics Price To Sales Ratio and its Payables Turnover accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unicycive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.

Price To Sales Ratio vs Payables Turnover

Price To Sales Ratio vs Payables Turnover Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Unicycive Therapeutics Price To Sales Ratio account and Payables Turnover. At this time, the significance of the direction appears to have strong relationship.

The correlation between Unicycive Therapeutics' Price To Sales Ratio and Payables Turnover is 0.77. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Payables Turnover in the same time period over historical financial statements of Unicycive Therapeutics, assuming nothing else is changed. The correlation between historical values of Unicycive Therapeutics' Price To Sales Ratio and Payables Turnover is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Unicycive Therapeutics are associated (or correlated) with its Payables Turnover. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Payables Turnover has no effect on the direction of Price To Sales Ratio i.e., Unicycive Therapeutics' Price To Sales Ratio and Payables Turnover go up and down completely randomly.

Correlation Coefficient

0.77

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Unicycive Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Unicycive Therapeutics sales, a figure that is much harder to manipulate than other Unicycive Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Most indicators from Unicycive Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Unicycive Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unicycive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.At this time, Unicycive Therapeutics' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 36.5 M in 2025, whereas Sales General And Administrative To Revenue is likely to drop 7.82 in 2025.

Unicycive Therapeutics fundamental ratios Correlations

	Total Current Liabilities	Net Tangible Assets	Retained Earnings	Accounts Payable	Total Current Assets	Common Stock	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Stockholder Equity	Net Debt	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Debt	Non Currrent Assets Other	Other Assets
Total Current Liabilities		0.79	-0.94	0.7	0.78	0.12	0.79	0.15	1.0	-0.31	-0.58	0.59	0.48	0.81	0.87	-0.2	0.94	0.94	1.0	-0.36	-0.34	0.99	-0.34	-0.17	-0.65	0.79
Net Tangible Assets	0.79		-0.91	0.94	0.9	-0.15	0.91	-0.12	0.8	0.18	-0.81	0.79	0.55	0.85	0.65	-0.53	0.95	0.95	0.8	0.12	-0.54	0.86	0.16	-0.34	-0.97	0.6
Retained Earnings	-0.94	-0.91		-0.87	-0.81	0.0	-0.82	-0.06	-0.94	0.19	0.65	-0.65	-0.5	-0.85	-0.84	0.34	-0.98	-0.98	-0.94	0.25	0.42	-0.96	0.22	0.22	0.8	-0.66
Accounts Payable	0.7	0.94	-0.87		0.81	-0.26	0.81	-0.03	0.71	0.16	-0.74	0.77	0.59	0.86	0.69	-0.46	0.88	0.87	0.71	0.11	-0.42	0.77	0.14	-0.22	-0.92	0.54
Total Current Assets	0.78	0.9	-0.81	0.81		-0.1	1.0	-0.02	0.79	0.35	-0.96	0.94	0.72	0.8	0.66	-0.39	0.88	0.89	0.79	0.29	-0.45	0.84	0.32	-0.26	-0.91	0.61
Common Stock	0.12	-0.15	0.0	-0.26	-0.1		-0.09	-0.35	0.14	-0.32	0.09	-0.07	-0.39	-0.17	0.33	-0.26	-0.04	-0.02	0.11	-0.37	-0.36	0.07	-0.32	-0.44	0.24	0.19
Total Assets	0.79	0.91	-0.82	0.81	1.0	-0.09		-0.01	0.8	0.33	-0.95	0.94	0.71	0.81	0.67	-0.39	0.89	0.9	0.8	0.27	-0.45	0.86	0.3	-0.27	-0.91	0.62
Short Long Term Debt Total	0.15	-0.12	-0.06	-0.03	-0.02	-0.35	-0.01		0.1	-0.27	0.15	-0.04	0.6	0.3	0.12	0.9	0.03	0.01	0.15	-0.16	0.87	0.08	-0.27	0.94	0.12	0.07
Other Current Liab	1.0	0.8	-0.94	0.71	0.79	0.14	0.8	0.1		-0.3	-0.6	0.6	0.45	0.79	0.87	-0.25	0.94	0.95	1.0	-0.36	-0.39	0.99	-0.33	-0.22	-0.65	0.79
Total Stockholder Equity	-0.31	0.18	0.19	0.16	0.35	-0.32	0.33	-0.27	-0.3		-0.57	0.54	0.35	0.0	-0.32	-0.31	-0.07	-0.06	-0.3	0.99	-0.19	-0.2	1.0	-0.16	-0.41	-0.24
Net Debt	-0.58	-0.81	0.65	-0.74	-0.96	0.09	-0.95	0.15	-0.6	-0.57		-0.98	-0.68	-0.64	-0.51	0.48	-0.73	-0.74	-0.59	-0.52	0.5	-0.67	-0.55	0.34	0.89	-0.41
Cash	0.59	0.79	-0.65	0.77	0.94	-0.07	0.94	-0.04	0.6	0.54	-0.98		0.75	0.71	0.6	-0.4	0.72	0.74	0.6	0.49	-0.41	0.66	0.52	-0.24	-0.87	0.47
Cash And Short Term Investments	0.48	0.55	-0.5	0.59	0.72	-0.39	0.71	0.6	0.45	0.35	-0.68	0.75		0.74	0.44	0.26	0.55	0.54	0.49	0.39	0.27	0.51	0.34	0.45	-0.63	0.36
Common Stock Total Equity	0.81	0.85	-0.85	0.86	0.8	-0.17	0.81	0.3	0.79	0.0	-0.64	0.71	0.74		0.77	-0.11	0.88	0.87	0.82	-0.02	-0.13	0.84	-0.02	0.07	-0.79	0.79
Common Stock Shares Outstanding	0.87	0.65	-0.84	0.69	0.66	0.33	0.67	0.12	0.87	-0.32	-0.51	0.6	0.44	0.77		-0.22	0.79	0.8	0.87	-0.36	-0.32	0.85	-0.34	-0.18	-0.53	0.77
Non Current Liabilities Total	-0.2	-0.53	0.34	-0.46	-0.39	-0.26	-0.39	0.9	-0.25	-0.31	0.48	-0.4	0.26	-0.11	-0.22		-0.38	-0.39	-0.2	-0.19	0.97	-0.29	-0.3	0.94	0.53	-0.17
Other Current Assets	0.94	0.95	-0.98	0.88	0.88	-0.04	0.89	0.03	0.94	-0.07	-0.73	0.72	0.55	0.88	0.79	-0.38		1.0	0.94	-0.13	-0.45	0.97	-0.1	-0.25	-0.86	0.73
Other Stockholder Equity	0.94	0.95	-0.98	0.87	0.89	-0.02	0.9	0.01	0.95	-0.06	-0.74	0.74	0.54	0.87	0.8	-0.39	1.0		0.95	-0.12	-0.47	0.98	-0.09	-0.27	-0.86	0.73
Total Liab	1.0	0.8	-0.94	0.71	0.79	0.11	0.8	0.15	1.0	-0.3	-0.59	0.6	0.49	0.82	0.87	-0.2	0.94	0.95		-0.35	-0.34	0.99	-0.33	-0.17	-0.66	0.79
Net Invested Capital	-0.36	0.12	0.25	0.11	0.29	-0.37	0.27	-0.16	-0.36	0.99	-0.52	0.49	0.39	-0.02	-0.36	-0.19	-0.13	-0.12	-0.35		-0.07	-0.26	0.99	-0.04	-0.35	-0.28
Short Long Term Debt	-0.34	-0.54	0.42	-0.42	-0.45	-0.36	-0.45	0.87	-0.39	-0.19	0.5	-0.41	0.27	-0.13	-0.32	0.97	-0.45	-0.47	-0.34	-0.07		-0.41	-0.18	0.97	0.5	-0.28
Capital Stock	0.99	0.86	-0.96	0.77	0.84	0.07	0.86	0.08	0.99	-0.2	-0.67	0.66	0.51	0.84	0.85	-0.29	0.97	0.98	0.99	-0.26	-0.41		-0.23	-0.23	-0.74	0.79
Net Working Capital	-0.34	0.16	0.22	0.14	0.32	-0.32	0.3	-0.27	-0.33	1.0	-0.55	0.52	0.34	-0.02	-0.34	-0.3	-0.1	-0.09	-0.33	0.99	-0.18	-0.23		-0.16	-0.38	-0.26
Short Term Debt	-0.17	-0.34	0.22	-0.22	-0.26	-0.44	-0.27	0.94	-0.22	-0.16	0.34	-0.24	0.45	0.07	-0.18	0.94	-0.25	-0.27	-0.17	-0.04	0.97	-0.23	-0.16		0.3	-0.17
Non Currrent Assets Other	-0.65	-0.97	0.8	-0.92	-0.91	0.24	-0.91	0.12	-0.65	-0.41	0.89	-0.87	-0.63	-0.79	-0.53	0.53	-0.86	-0.86	-0.66	-0.35	0.5	-0.74	-0.38	0.3		-0.45
Other Assets	0.79	0.6	-0.66	0.54	0.61	0.19	0.62	0.07	0.79	-0.24	-0.41	0.47	0.36	0.79	0.77	-0.17	0.73	0.73	0.79	-0.28	-0.28	0.79	-0.26	-0.17	-0.45

Click cells to compare fundamentals

Unicycive Therapeutics Account Relationship Matchups

Unicycive Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Current Liabilities	2.9M	2.1M	3.3M	17.5M	20.2M	21.2M
Retained Earnings	(5.9M)	(15.9M)	(34.0M)	(64.5M)	(58.1M)	(55.2M)
Accounts Payable	184K	713K	846K	821K	944.2K	540.1K
Total Current Assets	204K	18.4M	2.6M	13.4M	15.4M	16.2M
Common Stock	8K	9K	15K	35K	40.3K	21.3K
Total Assets	204K	18.7M	2.8M	14.2M	16.3M	17.1M
Short Long Term Debt Total	2.5M	306K	155K	811K	729.9K	679.4K
Other Current Liab	177K	1.1M	2.1M	16.4M	18.8M	19.8M
Total Stockholder Equity	(2.7M)	16.5M	(466K)	(3.8M)	(3.4M)	(3.3M)
Net Debt	2.5M	(16.3M)	(300K)	(8.9M)	(8.0M)	(7.6M)
Cash	0.0	16.6M	455K	9.7M	11.2M	5.9M
Non Current Assets Total	200.0K	333K	174K	792K	910.8K	956.3K
Liabilities And Stockholders Equity	204K	18.7M	2.8M	14.2M	16.3M	17.1M
Non Current Liabilities Total	2.7M	155K	1.0K	466K	419.4K	656.3K
Other Current Assets	204K	1.8M	2.2M	3.7M	4.3M	4.5M
Other Stockholder Equity	3.2M	32.4M	33.5M	60.7M	69.8M	73.3M
Total Liab	2.9M	2.3M	3.3M	18M	20.7M	21.7M
Net Invested Capital	(157K)	16.5M	(420K)	(3.8M)	(3.4M)	(3.2M)
Short Long Term Debt	2.5M	29K	46K	18K	16.2K	15.4K
Net Working Capital	(2.7M)	16.3M	(640K)	(4.1M)	(3.7M)	(3.5M)
Short Term Debt	2.5M	302K	310K	345K	310.5K	295.0K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for Unicycive Stock Analysis

When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Unicycive Price To Sales Ratio vs Payables Turnover Analysis

Price To Sales Ratio vs Payables Turnover

Price To Sales Ratio vs Payables Turnover Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Payables Turnover

Unicycive Therapeutics fundamental ratios Correlations

Unicycive Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Unicycive Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Unicycive Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Current Liab	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Total Current Liabilities
Total Assets	+ 1.0	Total Current Assets
Total Liab	+ 1.0	Other Current Liab
Net Working Capital	+ 1.0	Total Stockholder Equity
Other Stockholder Equity	+ 1.0	Other Current Assets

Cash	- 0.98	Net Debt
Other Stockholder Equity	- 0.98	Retained Earnings
Other Current Assets	- 0.98	Retained Earnings
Non Currrent Assets Other	- 0.97	Net Tangible Assets
Net Debt	- 0.96	Total Current Assets
Capital Stock	- 0.96	Retained Earnings